Assessing Biomarkers in Viral Infection

Adv Exp Med Biol. 2023:1412:159-173. doi: 10.1007/978-3-031-28012-2_8.

Abstract

Current biomarkers to assess the risk of complications of both acute and chronic viral infection are suboptimal. Prevalent viral infections like human immunodeficiency virus (HIV), hepatitis B and C virus, herpes viruses, and, more recently, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may be associated with significant sequelae including the risk of cardiovascular disease, other end-organ diseases, and malignancies. This review considers some biomarkers which have been investigated in diagnosis and prognosis of key viral infections including inflammatory cytokines, markers of endothelial dysfunction and activation and coagulation, and the role that more conventional diagnostic markers, such as C-reactive protein and procalcitonin, can play in predicting these secondary complications, as markers of severity and to distinguish viral and bacterial infection. Although many of these are still only available in the research setting, these markers show promise for incorporation in diagnostic algorithms which may assist to predict adverse outcomes and to guide therapy.

Keywords: Biomarker; C-reactive peptide; Coagulation; Inflammation; Procalcitonin; SARS-CoV-2; Viral infection.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • COVID-19* / diagnosis
  • Cytokines
  • Humans
  • SARS-CoV-2
  • Virus Diseases* / diagnosis

Substances

  • Biomarkers
  • Cytokines